Inflammatory Bowel Diseases
Cure8 research brief
Why This Matters
This large real‑world comparison helps show how different advanced therapies performed over 1 year in routine practice, highlighting that ustekinumab had strong outcomes overall while upadacitinib was most effective in patients with prior biologic exposure.
That information may be relevant when choosing or sequencing therapies.
Who Should Pay Attention
Clinicians, researchers, adult patients considering biologic/JAK therapy, and patients already on biologics
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This study pooled real‑world data from 1,406 UC patients treated between 2014 and 2024 and examined a strict primary outcome: continuous, steroid‑free clinical remission at 1 year without drug optimization, additional therapy, or AE‑driven discontinuation.
The drugs compared were infliximab, adalimumab, golimumab (anti‑TNFs), vedolizumab (anti‑integrin), ustekinumab (IL‑12/23 inhibitor), and the JAK inhibitors tofacitinib and upadacitinib. Ustekinumab was reported as the most effective overall and in bio‑naive patients, with the lowest adverse event rates.
Upadacitinib showed the highest efficacy among bio‑exposed (previously treated) patients and as later‑line therapy, but had higher adverse event rates; however, treatment withdrawal remained low. These findings come from an observational cohort and reflect real‑world use and practice patterns rather than randomized assignment.
Keep In Mind
Observational design and possible residual confounding limit causal conclusions; the primary endpoint required continuous, steroid‑free remission without optimization, which is a strict real‑world measure.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationInflammatory Bowel Diseases
PublisherOxford University Press (OUP)
AuthorsAndrea Cassinotti, Simone Saibeni, Rosanna Cannatelli +45 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedOct 29, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) Study in Ulcerative Colitis
The trial evaluated an investigational, non-drug vagal nerve stimulation device as a potential therapy for ulcerative colitis in adolescents and young adults, which could expand treatment options beyond conventional...
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Upadacitinib Is Associated with the Lowest Risk of Treatment Failure Among Advanced Therapies for Ulcerative Colitis: A Real-World Administrative Claims Study.
This large real-world study found upadacitinib was associated with lower risk of treatment failure and more corticosteroid-free stability compared with several other advanced therapies for ulcerative colitis —...
Beyond class switching in multi-refractory inflammatory bowel disease: Nine case reports and review of literature
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...